Literature DB >> 7689419

Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer.

G S Bova1, B S Carter, M J Bussemakers, M Emi, Y Fujiwara, N Kyprianou, S C Jacobs, J C Robinson, J I Epstein, P C Walsh.   

Abstract

Allelic loss studies have been instrumental in identifying tumor suppressor gene loci in a variety of cancers. In this study we analyzed prostate cancer specimens from 52 patients for allelic loss using 8 polymorphic probes for the short arm of chromosome 8. Overall, 32 of 51 (63%) informative tumors showed loss of at least one locus on chromosome 8p. The most frequently deleted region is observed at chromosome 8p22-8p21.2. Loss of one allele is identified in 14 of 23 (61%) tumors at D8S163, in 15 of 32 (47%) tumors at lipoprotein lipase, and in 20 of 29 (69%) tumors at MSR, all on 8p22. Loss of one allele is identified in 16 of 27 (59%) tumors at D8S220 at 8p21.3-8p21.2. In addition to frequent loss of one allele at the MSR locus, one metastatic prostate cancer sample demonstrated homozygous deletion of MSR sequences. Loci telomeric and centromeric to this region are largely retained. A chromosome 8p deletion map is constructed and defines the smallest region of overlap to a 14-cM interval at 8p22 between D8S163 and lipoprotein lipase, flanking the MSR locus. Evidence of chromosome 8q multiplication at locus D8S39 was detected in 5 of 32 (16%) tumors, all of which demonstrated loss with at least one probe on chromosome 8p. This study extends the previous finding of frequent loss of chromosome 8p in prostate cancer by defining a common region of loss of heterozygosity at 8p22 and a homozygous deletion of the MSR locus contained within this region. This is the first homozygous deletion identified in the genome of a human prostate cancer and the highest rate of loss yet reported on chromosome 8p in cancer. These results strongly suggest the presence of a tumor suppressor gene in this region which is frequently inactivated in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689419

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  79 in total

Review 1.  Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents.

Authors:  R Montironi; R Mazzucchelli; J R Marshall; P H Bartels
Journal:  J Clin Pathol       Date:  1999-11       Impact factor: 3.411

2.  High-resolution physical map and transcript identification of a prostate cancer deletion interval on 8p22.

Authors:  Z H Arbieva; K Banerjee; S Y Kim; S L Edassery; V S Maniatis; S K Horrigan; C A Westbrook
Journal:  Genome Res       Date:  2000-02       Impact factor: 9.043

3.  Genomewide linkage analysis of familial prostate cancer in the Japanese population.

Authors:  Hiroshi Matsui; Kazuhiro Suzuki; Nobuaki Ohtake; Seiji Nakata; Toshiyuki Takeuchi; Hidetoshi Yamanaka; Ituro Inoue
Journal:  J Hum Genet       Date:  2003-12-10       Impact factor: 3.172

4.  Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36.

Authors:  M Gibbs; J L Stanford; R A McIndoe; G P Jarvik; S Kolb; E L Goode; L Chakrabarti; E F Schuster; V A Buckley; E L Miller; S Brandzel; S Li; L Hood; E A Ostrander
Journal:  Am J Hum Genet       Date:  1999-03       Impact factor: 11.025

5.  NKX3.1 as a marker of prostatic origin in metastatic tumors.

Authors:  Bora Gurel; Tehmina Z Ali; Elizabeth A Montgomery; Shahnaz Begum; Jessica Hicks; Michael Goggins; Charles G Eberhart; Douglas P Clark; Charles J Bieberich; Jonathan I Epstein; Angelo M De Marzo
Journal:  Am J Surg Pathol       Date:  2010-08       Impact factor: 6.394

6.  Detection of deleted in malignant brain tumors 1 and runt-related transcription factor 3 gene expressions in bladder carcinoma.

Authors:  Yavuz Dodurga; Cığır Biray Avcı; N Lale Satiroglu-Tufan; Canten Tataroglu; Zehra Kesen; Z Ozlem Doğan; Sunde Yılmaz; Cumhur Gündüz
Journal:  Mol Biol Rep       Date:  2011-09-29       Impact factor: 2.316

Review 7.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.

Authors:  Lisa M Butler; Ylenia Perone; Jonas Dehairs; Leslie E Lupien; Vincent de Laat; Ali Talebi; Massimo Loda; William B Kinlaw; Johannes V Swinnen
Journal:  Adv Drug Deliv Rev       Date:  2020-07-23       Impact factor: 15.470

8.  A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49.

Authors:  Lawrence D True; Kent Buhler; Janna Quinn; Emily Williams; Peter S Nelson; Nigel Clegg; Jill A Macoska; Thomas Norwood; Alvin Liu; William Ellis; Paul Lange; Robert Vessella
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

9.  Sox7 Is an independent checkpoint for beta-catenin function in prostate and colon epithelial cells.

Authors:  Lizheng Guo; Diansheng Zhong; Stephen Lau; Xiuju Liu; Xue-Yuan Dong; Xiaodong Sun; Vincent W Yang; Paula M Vertino; Carlos S Moreno; Vijay Varma; Jin-Tang Dong; Wei Zhou
Journal:  Mol Cancer Res       Date:  2008-09       Impact factor: 5.852

10.  Palmitoylation of cytoskeleton associated protein 4 by DHHC2 regulates antiproliferative factor-mediated signaling.

Authors:  Sonia L Planey; Susan K Keay; Chen-Ou Zhang; David A Zacharias
Journal:  Mol Biol Cell       Date:  2009-01-14       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.